Publications

In the fight against the coronavirus (COVID-19) worldwide, we continue to offer our collaboration. Currently the need to provide quality medicines for human and veterinary use is especially noticeable. Our activity is focused on improving the level of the pharmaceutical quality system of manufacturers, which contributes to the promotion of safe and quality medicines on the market. The work of our experts continues in all areas.

      In today's rapidly changing world, for successful business development, it is very important to systematically analyze, evaluate trends and use the information received for timely and effective management decisions. Every year there is a development and change in regulatory requirements for pharmaceutical production. On the one hand, we see active growth in the industry as a whole.

        During the preparation phase of the 3rd All-Russia GMP conference, the State Institute of Drugs and Good Practices (SID & GP) received more than 100 questions from 34 open and anonymous sources. They were mostly about follow-up inspections and Corrective Action/Preventive Action (CAPA) plans. SID & GP experts analyzed the received information to determine the number of businesses planning to re-submit applications for follow-up inspections. Tentative assessment revealed 112 companies from 38 countries.